Cart 19 Product Products 7 333,00 € (empty)
No products
To be determined Shipping
7 333,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 19 items in your cart. There is 1 item in your cart.
Total products (tax excl.) 7 333,00 €
Total shipping (tax excl.) To be determined
Total (tax excl.) 7 333,00 €
Data sheet of Mme monoclonal antibody, clone LT10 (FITC)
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Mouse |
| Applications | Flow Cyt |
More info about Mme monoclonal antibody, clone LT10 (FITC)
| Brand: | Abnova |
| Reference: | MAB4348 |
| Product name: | Mme monoclonal antibody, clone LT10 (FITC) |
| Product description: | Mouse monoclonal antibody raised against native Mme. |
| Clone: | LT10 |
| Isotype: | IgG1 |
| Gene id: | 17380 |
| Gene name: | Mme |
| Gene alias: | 6030454K05Rik|C85356|CALLA|CD10|NEP |
| Gene description: | membrane metallo endopeptidase |
| Immunogen: | Mative purified Mme from mouse NALM-6 leukemia pre-B cell line. |
| Form: | Liquid |
| Recommend dilutions: | Flow Cytometry (20 ul in human blood cells 100 ul in whole blood or 106 cells in a suspension) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS (0.2% BSA, 0.09% sodium azide) |
| Storage instruction: | Store in the dark at 4°C. Do not freeze. Avoid prolonged exposure to light. Aliquot to avoid repeated freezing and thawing. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Conjugate tag: | FITC |
| Product type: | Primary antibodies |
| Host species: | Mouse |
| Antigen species / target species: | Human |
| Specificity: | This antibody reacts with CD10 antigen (CALLA - Common acute lymphatic leukemia antigen), a 100 KDa type II integral membrane protein. |
| Reactivity: | Human |
| Applications: | Flow Cyt |
| Shipping condition: | Blue Ice |
| Publications: | Differential expression of CD10 in prostate cancer and its clinical implication.Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. BMC Urol. 2007 Mar 2;7:3. |